Related Experiment Video
Updated: Aug 10, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Primary aldosteronism: treatment with trilostane
Cardiology
|January 1, 1985
Summary
Trilostane effectively treats primary aldosteronism by inhibiting aldosterone production. This study showed reduced aldosterone, lower blood pressure, and increased potassium in patients with adrenal adenoma or hyperplasia.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Primary aldosteronism is characterized by excessive aldosterone production.
- It can stem from adrenal adenoma or bilateral adrenal hyperplasia.
- This condition leads to hypertension and hypokalemia.
Purpose of the Study:
- To evaluate the efficacy of trilostane in treating primary aldosteronism.
- To assess trilostane's impact on aldosterone levels, blood pressure, and serum potassium.
Main Methods:
- Trilostane, a 3 beta-hydroxysteroid dehydrogenase inhibitor, was administered to 18 patients.
- The treatment duration was 12 weeks.
- Patients included those with adrenal adenoma (n=9) and bilateral adrenal hyperplasia (n=9).
Main Results:
- A significant decrease in plasma aldosterone was observed.
- Patients experienced a reduction in blood pressure.
- Serum potassium levels increased during trilostane therapy.
- Mild diarrhea occurred in 4 patients but did not necessitate treatment discontinuation.
Conclusions:
- Trilostane is an effective inhibitor of aldosterone biosynthesis.
- It is useful in managing primary aldosteronism in both adrenal adenoma and bilateral adrenal hyperplasia.
- Trilostane demonstrates a favorable safety profile for this condition.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: